Cryptotanshinone Inhibits Bladder Cancer Cell Malignant Progression in a Lipopolysaccharide-Induced Inflammatory Microenvironment through NLRP3 Inhibition

Figure 4

Cryptotanshinone (CTS) dose-dependently inhibited lipopolysaccharide (LPS)-induced NLRP3 and inflammatory cytokine overexpression in bladder cancer cells. In total, 5,637 cells were grown and pretreated with LPS, then treated with CTS, and finally subjected to (a) RT-qPCR analysis of NLRP3 mRNA and (b and c) Western blot analysis of NLRP3 protein. The cell culture supernatant was gathered and subjected to enzyme-linked immunosorbent assays (ELISAs) to determine the levels of (d) IL-1β, (e) IL-18, and (f) TNF-α. DMSO, dimethyl sulfoxide. , , , and .

(a)

(b)

(c)

(d)

(e)

(f)